Table 2.
PNS treatment information of the 20 trials included in the meta-analyses.
| Authors | Interventions (sample size) Dosage | Durations | Observations | Adverse incidences (%) |
|---|---|---|---|---|
| Guo et al. (90) | PNS(n = 100): XST Inj 200 mg/day | 3 weeks | ER | NO |
| CT(n = 100): MNT,ST | NR | |||
| He et al. (89) | PNS(n = 12): XSHT Inj 140 mg/day | 2 weeks | IHV,IEV | NR |
| CT(n = 12): MNT,VC,KCI | ||||
| Xu and Dong (72) | PNS(n = 42): XST FDP 400 mg/day | 4 weeks | ER,NDP | NR |
| CT(n = 40): DH,ICP,ST | ||||
| Li et al. (88) | PNS(n = 55): XST Inj 600 mg/day | 2 weeks | ER,NDP,IHV | Sr (5%) |
| CT(n = 60): AHT,CICP,ST | NO | |||
| Li and Yang (73) | PNS(n = 48): XST FDPI 400 mg/day) | 2 weeks | ER,NDS | NO |
| CT(n = 44): CAS | NR | |||
| Tian et al. (74) | PNS(n = 36): XST Inj 200 mg/day | 6 weeks | ER,NDP,NDS,IHV | NR |
| CT(n = 30): MNT,FRS,ST | ||||
| Li and Sun (75) | PNS(n = 29): XST Inj 500 mg/day | 4 weeks | ER | NR |
| CT(n = 31): DH,NTM,BCA,ST | ||||
| Xie et al. (76) | PNS(n = 24): XSHT Inj 400 mg/day | 10 weeks | ER,BI | NO |
| CT(n = 22): DH,CICP,ST | ||||
| Chen et al. (77) | PNS(n = 22): XST FDPI 800 mg/day | 2 weeks | NDS | NO |
| CT(n = 21): DH,CICP,AHT,ST | ||||
| Dong and Wang (78) | PNS(n = 40): XST FDPI 400 mg/day | 2 weeks | ER,NDP | NR |
| Zhang et al. (71) | CT(n = 38): DH,CICP,ST | 2 weeks | ER | NO |
| PNS(n = 65): LLT Inj 250 mg/day | ||||
| CT(n = 65): MNT, MGSO4,KCL, | ||||
| INS, Aceglutamide Inj | ||||
| Zhou et al. (79) | PNS(n = 70): XST FDPI 400 mg/day | 2 weeks | ER,NDS | NR |
| CT(n = 70): CICP,MNT,FRS Inj, | ||||
| GFI,BCA,AHT,ST | ||||
| Zheng (80) | PNS(n = 22): XSHT Inj 300 mg/day | 3 weeks | NDS | NR |
| CT(n = 19): ST | ||||
| Tang et al. (81) | PNS(n = 63): XSHT Inj 300 mg/day | 3 weeks | IHV | NR |
| CT(n = 63): MNT,VC,ST | ||||
| Song (82) | PNS(n = 39): XSHT Inj powder 450 mg/day | 4 weeks | IHV,IEV | NR |
| CT(n = 39): CICP, AHT,ST | ||||
| Ding HY 2008 (83) | PNS(n = 15): XST FDPI 200 mg/day | 2 weeks | BI | NR |
| CT(n = 17):AHT, MNT,CICP, ST | ||||
| Yuan HY 2008 (84) | PNS(n = 67): XST Inj 750 mg/day | 2 weeks | ER,NDP | NO |
| CT(n = 66): MNT,GFI | NR | |||
| Ding and Geng (85) | PNS(n = 86): XSHT Inj 175 mg/day | 3 weeks | ER,IHV,IEV | NO |
| CT(n = 86): CICP, AHT,ST | ||||
| Gao HY 2008 (86) | PNS(n = 28): XST Inj 250 mg/day | 2 weeks | NDS | NR |
| CT(n = 24): MNT,CICP, AHT,ST | ||||
| Chen (87) | PNS(n = 61): SQZG 350 mg/day | 2 weeks | ER,NDP,IHV | NR |
| CT(n = 60): CICP, AHT,ST |
AHT, anti-hypertensive treatment; BCA, brain cell activators; BI, Barthel index; CAS, citicoline sodium; CICP, control of intracerebral pressure; DH, dehydration; ER, effectiveness rate; DPI, freeze-dry powder injector; FRS, furosemide; GFI, glycerol and fructose injection; IEV, intracerebral edema volume; IHV, intracerebral hematoma volume; Inj, injection; INS, insulin; KCI, potassium chloride; MGSO4, magnesium sulfate; MNT, mannitol; NDP, number of death patients; NDS, neurological deficit score; NR, not reported; NTM, neurotrophy medicine; PNS, Panax notoginseng saponin; CT, current treatment; SQZG, sanqi zaogan; Sr, skin rashes; ST, symptomatic treatment; VC, vitamin C; XSHT, Xue Shuan Tong; XST, Xue Sai Tong (Xuesaitong).